Issuance of Letter of Confirmation – 07/11/2023

Loss of Share Certificates – 30/08/2023

Issuance of Letter of Confirmation – 18/10/2023

Loss of Share Certificates – 02/10/2023

Issuance of Letter of Confirmation – 20/09/2023

Loss of Share Certificates – 30/08/2023

Intimation regarding completion of US FDA inspection – 26.05.2023

Issuance of Letter of Confirmation – 22/05/2023

Loss of Share Certificates – 08/05/2023

Related Party Disclosure_H2FY23

Announcement under Regulation 30 (LODR)- Upgrade of Credit Rating_25 April 2023

Issuance of Letter of Confirmation_14.02.2023

Loss of Share Certificates – 01/02/2023

Issuance of Letter of Confirmation_13.12.2022

Loss of Share Certificates

Announcement under Regulation 30 (LODR)- Upgrade of Credit Rating_16 November 2022

Related Party Disclosure_H1FY2023

Related Party Disclosure_Half Year ended-(31-03-2022)

Secretarial Compliance Report FY 2022

Disclosure under Regulation 30 of SEBI_Credit Rating_21 April 2022

Reporting under SEBI (PIT) Regulation, 2015_December 27, 2021

Disclosure under Regulation 30 of SEBI (LODR)_Demise

Related Party Disclosure_Half Year ended-(30-09-2021)

SE Intimation Credit Rating18 Aug 21

Related Party Disclosure_Half Year ended-(31-03-2021)

Disclosure under Regulation 30 of SEBI (LODR)_23 April 2021

Disclosure under Regulation 30 of SEBI_Credit Rating_14 April 2021

Analysts Institutional Investor Meet_31 Dec 2020

Analysts Institutional Investor Meet_25 Nov 2020

Analysts Institutional Investor Meet_18 Nov 2020

Disclosure Under Regulation 30-LODR

Update_ Successful USFDA of Unit 2 (07.05.2020)

Withdrawal of Credit Rating from CARE Ratings Ltd. (28 April 2020)

SE Intimation Credit Rating (20 March 2020)

Disclosure Under Regulation 30 of SEBI

Successful USFDA Update of Unit 2 (07.02.2020)

Related Party Disclosure_ Half Year ended- (31-03-2019)

Rating Rationale from CARE Ratings Ltd (02 August 2019)

Successful USFDA Update of Unit 1 (21-06-2019)

Disclosure under Regulation 30 of SEBI (Update)

Disclosure under Regulation 30 of SEBI

Rating Rationale from CARE Ratings Ltd

Successful USFDA Inspection of Unit 2 (29-11-18)

Neuland Acquires New Facility (13-12-17)

Update on Purchase of Manufacturing Facility (12-12-17)

Update on Nanakramguda Project (21-05-17)

The Listing Agreement Pertaining to Media Companies and/or their Associates

Draft Letter of Offer (26-03-14)

Letter of Offer (20-03-12)

Contact details for Materiality Disclosure

CG Report – Sep 2023

CG Report – June 2023